Kiniksa Pharmaceuticals International, plc (KNSA) Financial Statements
Kiniksa Pharmaceuticals International, plc (KNSA) reported trailing twelve-month revenue of $840.8M (up 58.9% year on year) and net income of $80.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $182.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 6.0B
- P/E TTM
- 78.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 38.5 | 220.2 | 270.3 | 423.2 | 677.6 | 840.8 | |
| Gross profit | 29.4 | 197.3 | 236.9 | 362.3 | 599.9 | 755.3 | |
| Research & development | 99.3 | 65.5 | 76.1 | 111.6 | 96.9 | 127.1 | |
| Operating income | -156.6 | 9.8 | -25.2 | -45.6 | 77.2 | 100.3 | |
| Pre-tax income | -156.5 | 11.0 | -16.7 | -36.2 | 88.9 | 114.3 | |
| Income tax | 1.4 | -172.3 | -30.7 | 7.0 | 29.9 | 33.6 | |
| Net income | -157.9 | 183.4 | 14.1 | -43.2 | 59.0 | 80.7 | |
| Diluted EPS ($) | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 | 0.98 | |
| Diluted shares (mn) | 68.6 | 70.4 | 71.9 | 71.4 | 79.0 | — |
USD millions · SEC XBRL
Kiniksa Pharmaceuticals International, plc — questions
- What is Kiniksa Pharmaceuticals International, plc's revenue?
- $840.8M over the twelve months to 2026-06-30, up 58.9% year on year, from its 10-Q and 10-K filings.
- What is Kiniksa Pharmaceuticals International, plc's net income?
- $80.7M over the twelve months to 2026-06-30.
- What is Kiniksa Pharmaceuticals International, plc's free cash flow?
- $182.8M over the twelve months to 2026-06-30.
- What are Kiniksa Pharmaceuticals International, plc's diluted earnings per share?
- $0.98 over the twelve months to 2026-06-30.
Every figure on this page comes from Kiniksa Pharmaceuticals International, plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.